Literature DB >> 2661512

Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

T Nishino1, Y Maeda, E Ohtsu, S Koizuka, T Nishihara, H Adachi, K Okamoto, M Ishiguro.   

Abstract

The new oral penem antibiotic SUN5555 shows broad antibacterial activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria. SUN5555 is highly stable against various beta-lactamases. It binds preferentially to the penicillin-binding proteins 2 and 1A of Escherichia coli.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2661512     DOI： 10.7164/antibiotics.42.977

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


  9 in total

1.  Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa.

Authors:  Kiyomi Okamoto; Naomasa Gotoh; Takeshi Nishino
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents.

Authors:  T Yamamoto; G B Nair; M J Albert; C C Parodi; Y Takeda
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

4.  Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay.

Authors:  K Okamoto; N Gotoh; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  Antibacterial activity of WY-49605 compared with those of six other oral agents and selection of disk content for disk diffusion susceptibility testing.

Authors:  P C Fuchs; A L Barry; D L Sewell
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

6.  Comparative antimicrobial activities of the penem WY-49605 (SUN5555) against recent clinical isolates from five U.S. medical centers.

Authors:  D Sewell; A Barry; S Allen; P Fuchs; J McLaughlin; M Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

7.  In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.

Authors:  M Tsuji; Y Ishii; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

8.  Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

9.  In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.

Authors:  E Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.